Early and Long Term Results of Our Open Heart Surgical Operations in the Presence of Active Oncological Diseases

Abstract

Introduction: Active cancer and heart disease, which share similar environmental and biological characteristics, can occur concomitantly. Open heart surgery may be required for these patients when indicated. This study aims to demonstrate the early and long-term results and discuss the intervention strategy in patients with different types of active malignancies, who underwent open-heart surgery. Patients and Methods: Between January 2012 and May 2020, open-heart surgery was performed on 10 patients with active malignancies. The mean age was 65.5 (52-77), and four of the patients were female. Two patients were operated on urgently due to advanced pleural effusion. AVR+CABG, CABG, CABG+left upper lobectomy, and AVR+MVR were performed in four patients with lung cancer; AVR+CABG were performed in one patient with colon cancer; CABG was performed in four patients each with one of the following conditions: lymphoma, breast cancer, essential thrombocytosis, meningioma); and mass resection operation from the left atrium and left ventricle was performed in one patient with osteosarcoma. Results: Eight patients were discharged and two patients died in the early postoperative period. Postoperative left hemiparesis developed in one patient. Six-month, one-year and five-year survival rates were 79%, 37.5% and 25%, respectively. Conclusion: Open-heart surgery can be successfully performed with acceptable mortality and morbidity rates on the high-risk patient group with active cancer.

Keywords

• Coronary artery bypass grafting
• cardiopulmonary bypass
• lung cancer
• breast cancer

References

1. 1. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016;133(11):1104-14. [Crossref]
2. 2. Handy CE, Quispe R, Pinto X, Blaha MJ, Blumenthal RS, Michos ED, et al. Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger. Circulation 2018;138(7):727-34. [Crossref]
3. 3. Kreatsoulas C, Anand SS, Subramanian SV. An emerging double burden of disease: the prevalence of individuals with cardiovascular disease and cancer. J Intern Med 2014;275(5):494-505. [Crossref]
4. 4. Tabata N, Sueta D, Yamamoto E, Takashio S, Arima Y, Araki S, et al. Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. Eur Heart J Qual Care Clin Outcomes 2018;4(4):290-300. [Crossref]
5. 5. Tsuji Y, Morimoto N, Tanaka H, Okada K, Matsuda H, Tsukube T, et al. Surgery for gastric cancer combined with cardiac and aortic surgery. Arch Surg 2005;140(11):1109-14. [Crossref]
6. 6. Zhu Y, Toth AJ, Lowry AM, Blackstone EH, Hill BT, Mick SL. Cardiac surgery outcomes in patients with chronic lymphocytic leukemia. Ann Thorac Surg 2018;105(4):1182-91. [Crossref]
7. 7. Litmathe J, Atmaca N, Menghesha D, Krian A. Combined procedures using the extracorporeal circulation and urologic tumor operation-experiences in six cases. Interact Cardiovasc Thorac Surg 2004;3(1):132-5. [Crossref]
8. 8. Guha A, Dey AK, Arora S, Cavender MA, Vavalle JP, Sabik JF III et al. Contemporary trends and outcomes of percutaneous and surgical aortic valve replacement in patients with cancer. J Am Heart Assoc 2020;9(2):e014248. [Crossref]

9. 9. Garatti A, D’Ovidio M, Saitto G, Daprati A, Canziani A, Mossuto E, et al. Coronary artery bypass grafting in patients with concomitant solid tumours: early and long-term results. Eur J Cardiothorac Surg 2020;58(3):528-36. [Crossref]
10. 10. Nardi P, Pellegrino A, Pugliese M, Bovio E, Chiariello L, Ruvolo G. Cardiac surgery with extracorporeal circulation and concomitant malignancy: early and long-term results. J Cardiovasc Med 2016;17(2):152-9. [Crossref]
11. 11. Kadri AN, Bernardo M, Assar SZ, Werns S, Abbas AE. Surgical versus transcatheter aortic valve replacement in patients with malignancy. Cardiovasc Revasc Med 2021;23:59-65. [Crossref]
12. 12. Potapov EV, Zurbrügg HR, Herzke C, Srock S, Riess H, Sodian R, et al. Impact of cardiac surgery using cardiopulmonary bypass on course of chronic lymphatic leukemia: a case-control study. Ann Thorac Surg 2002;74(2):384-9. [Crossref]
13. 13. Carrascal Y, Gualis J, Arévalo A, Fulquet E, Flórez S, Rey J, et al. Cardiac surgery with extracorporeal circulation in cancer patients: influence on surgical morbidity and mortality and on survival. Rev Esp Cardiol 2008;61(4):369-75. [Crossref]
14. 14. Fecher AM, Birdas TJ, Haybron D, Papasavas PK, Evers D, Caushaj PF. Cardiac operations in patients with hematologic malignancies. Eur J Cardiothorac Surg 2004;25(4):537-40. [Crossref]
15. 15. Zhu Y, Toth AJ, Lowry AM, Blackstone EH, Hill BT, Mick SL. Cardiac surgery outcomes in patients with chronic lymphocytic leukemia. Ann Thorac Surg 2018;105(4):1182-91. [Crossref]
16. 16. Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2019;40(22):1790-800. [Crossref]
17. 17. Ciriaco P, Carretta A, Calori G, Mazzone P, Zannini P. Lung resection for cancer in patients with coronary arterial disease: analysis of short-term results. Eur J Cardiothorac Surg 2002;22(1):35-40. [Crossref]